Rapid Micro Biosystems Sees Q4 Revenue of $11.35M, EPS -$0.22
Rapid Micro Biosystems will report Q4 2025 results on March 12, with analysts expecting $11.35M revenue and -$0.22 EPS. Full-year 2025 revenue estimates rose to $32.98M while 2026 forecasts climbed to $40.13M, and the $8.00 average price target implies a 93% upside.
1. Q4 2025 Preview
Rapid Micro Biosystems is scheduled to report Q4 2025 results on March 12, with analysts forecasting $11.35 million in revenue and -$0.22 per share earnings.
2. Full-Year Estimates Revision
Over the past 90 days, full-year 2025 revenue estimates increased from $32.83 million to $32.98 million, and 2026 projections rose from $39.88 million to $40.13 million, while EPS forecasts held at -$1.00 for 2025 and -$0.86 for 2026.
3. Q3 Performance
In the quarter ended September 30, 2025, the company reported $7.84 million in revenue, beating estimates by 1.14%, and posted a -$0.26 EPS miss of 6.12%, triggering a 12.73% one-day share gain.
4. Analyst Targets and Recommendations
Analysts maintain a uniform one-year price target of $8.00, implying a 93.47% upside, contrasted with a private valuation of $2.22 suggesting a 46.3% downside; broker consensus sits at a 1.8 rating, indicating an outperform stance.